123,000,000 shares, representing 4.38% of the issued share capital, were issued toMr. Peng Yi,at HK $0.122 for a total net proceeds of HK $14,990,000
During the year, the principal activities of the Company and its subsidiaries (collectively referred to as the “Group”) are (i) the manufacture and sale of packaging products; (ii) investments and trading in securities and money lending; and (iii) production and sale of Chlamydomonas reinhardtii, micro-algae and related products.
"Disclaimer of Opinion" "We were engaged to audit the consolidated financial statements of Touyun Biotech Group Limited (the “Company”) and its subsidiaries (collectively referred to as the “Group”)... We do not express an opinion on the consolidated financial statements of the Group. Because of the significance of the matter described in the Basis for Disclaimer of Opinion section of our report, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these consolidated financial statements."
"the Group will communicate closely with Mr. Wang Liang, a director of the Company, and Ms. Qiao Yanfeng, a shareholder of the Company, to request them to commit not to demand repayment of the amounts due to them (with an aggregate amount of HK$124,605,000 as at 31 December 2025), or extend the advances until the Group has sufficient cash to repay" (Note: In 2024, the shareholder Ms. Qiao Yanfeng waived an amount due to her of HK$2,145,000 as a deemed capital contribution.)
During the year, the Group has been actively inspecting its financial position on a regular basis.""The Directors are of the view that, upon and after the implementation of the plans and measures being or to be prepared and executed by the Group, the Group's financial position will be restored and the uncertainties relating to going concern will be properly resolved. Accordingly, after taking into account the active plans and measures being or to be implemented by the Group to mitigate its liquidity pressure and improve its financial position, the Directors are of the view that the Group will have sufficient working capital to satisfy its financial obligations as and when they fall due within the next twelve months from 31 December 2025. Accordingly, the Directors consider that it is appropriate to prepare the consolidated financial statements for the year ended 31 December 2025 on a going concern basis."
